RHOA and systemic sclerosis: In accordance with this hypothesis, MDM from SSc patients have reduced efferocytosis capacities and a treatment by the ROCK inhibitor Y27632 partly restores this defective efferocytosis, confirming the involvement of RhoA/ROCK in this SiO2-associated fibrotic disorder.